Literature DB >> 11274233

Role of CFTR in autosomal recessive polycystic kidney disease.

Koichi Nakanishi1, William E Sweeney1, Katherine Macrae Dell1, Calvin U Cotton1, Ellis D Avner1.   

Abstract

An extensive body of in vitro data implicates epithelial chloride secretion, mediated through cystic fibrosis transmembrane conductance regulator (CFTR) protein, in generating or maintaining fluid filled cysts in MDCK cells and in human autosomal dominant polycystic kidney disease (ADPKD). In contrast, few studies have addressed the pathophysiology of fluid secretion in cyst formation and enlargement in autosomal recessive polycystic kidney disease (ARPKD). Murine models of targeted disruptions or deletions of specific genes have created opportunities to examine the role of individual gene products in normal development and/or disease pathophysiology. The creation of a murine model of CF, which lacks functional CFTR protein, provides the opportunity to determine whether CFTR activity is required for renal cyst formation in vivo. Therefore, this study sought to determine whether renal cyst formation could be prevented by genetic complementation of the BPK murine model of ARPKD with the CFTR knockout mouse. The results of this study reveal that in animals that are homozygous for the cystic gene (bpk), the lack of functional CFTR protein on the apical surface of cystic epithelium does not provide protection against cyst growth and subsequent decline in renal function. Double mutant mice (bpk -/-; cftr -/-) developed massively enlarged kidneys and died, on average, 7 d earlier than cystic, non-CF mice (bpk -/-; cftr +/+/-). This suggests fundamental differences in the mechanisms of transtubular fluid secretion in animal models of ARPKD compared with ADPKD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274233     DOI: 10.1681/ASN.V124719

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  13 in total

Review 1.  Role of kidney chloride channels in health and disease.

Authors:  I Elias Veizis; Calvin U Cotton
Journal:  Pediatr Nephrol       Date:  2006-11-16       Impact factor: 3.714

2.  Acute renal failure in people with cystic fibrosis.

Authors:  Kevin W Southern
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 3.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 4.  Drug discovery for polycystic kidney disease.

Authors:  Ying Sun; Hong Zhou; Bao-xue Yang
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

5.  Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.

Authors:  Guangfu Jia; Michelle Kwon; Huan Ling Liang; Jordan Mortensen; Vani Nilakantan; William E Sweeney; Frank Park
Journal:  Pediatr Nephrol       Date:  2010-03-13       Impact factor: 3.714

Review 6.  Epidermal growth factor-mediated proliferation and sodium transport in normal and PKD epithelial cells.

Authors:  Nadezhda N Zheleznova; Patricia D Wilson; Alexander Staruschenko
Journal:  Biochim Biophys Acta       Date:  2010-10-16

Review 7.  Functional and therapeutic importance of purinergic signaling in polycystic kidney disease.

Authors:  Daria V Ilatovskaya; Oleg Palygin; Alexander Staruschenko
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-21

8.  20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease.

Authors:  Frank Park; William E Sweeney; Guangfu Jia; Richard J Roman; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

9.  Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD.

Authors:  Frank Park; William E Sweeney; Guangfu Jia; Talha Akbulut; Benjamin Mueller; J Russell Falck; Saritha Birudaraju; Richard J Roman; Ellis D Avner
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-07

10.  Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy.

Authors:  Chatchai Muanprasat; N D Sonawane; Danieli Salinas; Alessandro Taddei; Luis J V Galietta; A S Verkman
Journal:  J Gen Physiol       Date:  2004-08       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.